Telcon RF Pharmaceutical (XKRX:200230) ROCE % : -47.16% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Telcon RF Pharmaceutical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Telcon RF Pharmaceutical's annualized ROCE % for the quarter that ended in Dec. 2024 was -47.16%.

Telcon RF Pharmaceutical ROCE % Historical Data

The historical data trend for Telcon RF Pharmaceutical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telcon RF Pharmaceutical ROCE % Chart

Telcon RF Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-37.13

-15.02

-42.58

15.28

-24.02

Telcon RF Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															17.05	-27.92	-38.17	17.27	-47.16

Telcon RF Pharmaceutical ROCE % Calculation

Telcon RF Pharmaceutical's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-22740.082	/	( ( (140414.917 - 34923.951)	+	(153588.08 - 69720.075) )	/ 2 )
	=	-22740.082	/	( (105490.966	+	83868.005)	/ 2 )
	=	-22740.082	/	94679.4855
	=	-24.02 %

Telcon RF Pharmaceutical's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-42447.104	/	( ( (152716.59 - 56567.965)	+	(153588.08 - 69720.075) )	/ 2 )
	=	-42447.104	/	( ( 96148.625	+	83868.005 )	/ 2 )
	=	-42447.104	/	90008.315
	=	-47.16 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Telcon RF Pharmaceutical (XKRX:200230) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Telcon RF Pharmaceutical ROCE % Related Terms

Thank you for viewing the detailed overview of Telcon RF Pharmaceutical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Telcon RF Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Telcon RF Pharmaceutical Inc (XKRX:200230) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

684, Dongtangiheung-ro, Giheung-gu, Gyeonggi-do, Yongin-si, KOR, 17102

Website

http://www.telcon.co.kr

Telcon RF Pharmaceutical Inc manufactures wireless communication equipment. It develops connectors for input and output ports, board-to-board, cable assembly, and board-to-mount used in wireless communication equipment. The company also supplies RF coaxial connectors. The company operates in the RF Division and Pharmaceuticals & Biotechnology segments. The majority of its revenue is generated from Pharmaceuticals & Biotechnology, which produces and sells liquids, tablets, pills, capsules, etc.

Telcon RF Pharmaceutical Headlines

No Headlines